Abstract
Definitive chemoradiation followed by durvalumab is the standard of care in Stage III NSCLC. EGFR-mutant NSCLC is treated by EGFR-TKIs in stage IV disease with a higher ORR compared to chemotherapy. This study tested the feasibility and efficacy of osimertinib as systemic induction therapy before definitive radiation therapy in EGFR-mutant stage III NSCLC patients. Growth tumor volume (GTV) and ORR were the primary outcomes, while toxicity and DFS were secondary outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
